AbbVie Files 8-K on Financials and Debt

Ticker: ABBV · Form: 8-K · Filed: 2024-04-26T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, debt, sec-filing

Related Tickers: ABBV

TL;DR

AbbVie dropped an 8-K detailing financials and debt maturities.

AI Summary

AbbVie Inc. filed an 8-K on April 26, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with specific references to various senior notes due in 2024, 2027, 2028, 2029, and 2031.

Why It Matters

This filing provides investors with an update on AbbVie's financial performance and details its outstanding debt obligations, which are crucial for assessing the company's financial health.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not appear to contain any unexpected or negative news.

Key Numbers

2024 — Senior Notes Due (AbbVie has senior notes maturing in 2024.)
2027 — Senior Notes Due (AbbVie has senior notes maturing in 2027.)
2028 — Senior Notes Due (AbbVie has senior notes maturing in 2028.)
2029 — Senior Notes Due (AbbVie has senior notes maturing in 2029.)
2031 — Senior Notes Due (AbbVie has senior notes maturing in 2031.)

Key Players & Entities

AbbVie Inc. (company) — Filer of the 8-K
2024-04-26 (date) — Filing date
1 NORTH WAUKEGAN ROAD (address) — Company's business and mail address
NORTH CHICAGO (city) — Company's business and mail city
IL (state) — Company's business and mail state
60064 (zip_code) — Company's business and mail zip code
001-35565 (filing_number) — SEC file number for AbbVie

FAQ

What specific financial results are being reported in this 8-K?

The 8-K filing indicates it is for 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of the results are not provided in this excerpt.

What is the purpose of filing an 8-K for 'Results of Operations and Financial Condition'?

Companies file an 8-K under Item 2.02 (Results of Operations and Financial Condition) to report material information regarding their financial results, often when they announce earnings.

Which specific senior notes are mentioned in the filing?

The filing mentions senior notes due in 2024, 2027, 2028, 2029, and 2031, with specific coupon rates indicated for some (e.g., 0.750%, 1.250%, 2.125%, 2.625%, 3.750%).

What is AbbVie's Standard Industrial Classification (SIC) code?

AbbVie's SIC code is 2834, which corresponds to 'Pharmaceutical Preparations'.

When is AbbVie's fiscal year end?

AbbVie's fiscal year ends on December 31st.

From the Filing

0001551152-24-000016.txt : 20240426 0001551152-24-000016.hdr.sgml : 20240426 20240426074316 ACCESSION NUMBER: 0001551152-24-000016 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240426 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240426 DATE AS OF CHANGE: 20240426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24878736 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 abbv-20240426.htm 8-K abbv-20240426 0001551152 false 0001551152 2024-04-26 2024-04-26 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-04-26 2024-04-26 0001551152 exch:XCHI us-gaap:CommonStockMember 2024-04-26 2024-04-26 0001551152 abbv:Sec1.375SeniorNotesDue2024Member exch:XNYS 2024-04-26 2024-04-26 0001551152 exch:XNYS abbv:Sec1250SeniorNotesDue2024Member 2024-04-26 2024-04-26 0001551152 exch:XNYS abbv:Sec0.750SeniorNotesDue2027Member 2024-04-26 2024-04-26 0001551152 abbv:Sec2.125SeniorNotesdue2028Member exch:XNYS 2024-04-26 2024-04-26 0001551152 abbv:Sec2625SeniorNotesDue2028Member exch:XNYS 2024-04-26 2024-04-26 0001551152 exch:XNYS abbv:Sec2125SeniorNotesDue2029Member 2024-04-26 2024-04-26 0001551152 abbv:Sec1.250SeniorNotesdue2031Member exch:XNYS 2024-04-26 2024-04-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  _____________________________________________________ FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): April 26, 2024   ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware   001-35565   32-0375147 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)  _____________________________________________________ 1 North Waukegan Road North Chicago ,  Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐                       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchang